Randomized controlled phase II trial of glatiramer acetate in ALS

P. H. Gordon, C. Doorish, J. Montes, R. L. Mosely, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, H. E. Gendelman, S. Przedborski, H. Mitsumoto

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.

Original languageEnglish (US)
Pages (from-to)1117-1119
Number of pages3
Issue number7
StatePublished - Apr 2006

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Randomized controlled phase II trial of glatiramer acetate in ALS'. Together they form a unique fingerprint.

Cite this